With the aid of a proteasome denaturation cascade, EGCG decreases the accumulation of pulmonary fibrosis-associated mutant surfactant protein-A2 (SP-A2), but the proteasomal antagonist MG-132 can counteract the EGCG-mediated aggregate diminution [116]. Here, SFTPA2 is linked to pulmonary fibrosis.